Q3 EPS Estimates for NeoGenomics Boosted by Leerink Partnrs

NeoGenomics, Inc. (NASDAQ:NEO - Free Report) - Equities researchers at Leerink Partnrs increased their Q3 2025 earnings per share estimates for shares of NeoGenomics in a report released on Tuesday, February 18th. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $0.00 per share for the quarter, up from their previous forecast of ($0.01). The consensus estimate for NeoGenomics' current full-year earnings is ($0.20) per share. Leerink Partnrs also issued estimates for NeoGenomics' Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.04 EPS and FY2027 earnings at $0.28 EPS.

Several other equities analysts have also weighed in on the stock. Jefferies Financial Group assumed coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 target price on the stock. Bank of America lowered their price objective on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. Benchmark downgraded NeoGenomics from a "buy" rating to a "hold" rating in a research report on Monday, January 13th. The Goldman Sachs Group lowered their price target on NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Finally, Needham & Company LLC reduced their price objective on shares of NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, NeoGenomics has an average rating of "Moderate Buy" and an average price target of $19.80.

Remove Ads

NeoGenomics Trading Down 2.6 %

NASDAQ:NEO traded down $0.29 during trading hours on Friday, hitting $10.88. The company had a trading volume of 1,299,972 shares, compared to its average volume of 1,192,398. NeoGenomics has a 1 year low of $10.62 and a 1 year high of $19.11. The company has a market cap of $1.40 billion, a P/E ratio of -17.55 and a beta of 1.23. The company has a 50-day moving average of $15.01 and a 200 day moving average of $15.41. The company has a current ratio of 1.98, a quick ratio of 1.91 and a debt-to-equity ratio of 0.38.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business had revenue of $172.00 million for the quarter, compared to analysts' expectations of $173.40 million.

Hedge Funds Weigh In On NeoGenomics

Several institutional investors have recently modified their holdings of NEO. PNC Financial Services Group Inc. boosted its holdings in NeoGenomics by 5.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 15,610 shares of the medical research company's stock valued at $257,000 after purchasing an additional 770 shares during the period. Summit Investment Advisors Inc. raised its position in NeoGenomics by 6.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 13,339 shares of the medical research company's stock valued at $220,000 after purchasing an additional 863 shares in the last quarter. Fernwood Investment Management LLC boosted its stake in shares of NeoGenomics by 1.0% in the 3rd quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company's stock valued at $1,320,000 after buying an additional 900 shares during the period. FMR LLC boosted its stake in shares of NeoGenomics by 7.6% in the 3rd quarter. FMR LLC now owns 13,255 shares of the medical research company's stock valued at $196,000 after buying an additional 931 shares during the period. Finally, Blue Trust Inc. grew its position in shares of NeoGenomics by 42.3% during the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company's stock worth $46,000 after buying an additional 987 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company's stock.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.